Minervax

Hellerup, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

$57.4M raised

Oct 2023

Venture - Series Unknown

Top Investors

European Investment BankOrbiMedEQT Life SciencesWellington PartnersNovo Holdings

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Minervax raised?

Minervax has raised $57.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2023.

Who are Minervax's investors?

Minervax's investors include European Investment Bank, OrbiMed, EQT Life Sciences, Wellington Partners, Novo Holdings.

Where is Minervax headquartered?

Minervax is headquartered in Hellerup, Denmark.

What does Minervax do?

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

What stage is Minervax at?

Minervax is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 11, 2023.

MLA

"Minervax — Funding & Investors." VCBacked, October 11, 2023, https://www.vcbacked.co/company/minervax. Accessed June 7, 2026.

APA

VCBacked. (2023). Minervax — Funding & Investors. Retrieved June 7, 2026, from https://www.vcbacked.co/company/minervax

Wikipedia (cite web)

{{cite web |title=Minervax — Funding & Investors |url=https://www.vcbacked.co/company/minervax |website=VCBacked |access-date=June 7, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 11, 2023.